ClinicalTrials.gg
CompletedNCT06874114RE-ENGAGEUpdated Oct 6, 2026

An Observational Study to Learn More About Treatment Patterns and Factors Determining the Choice of Treatment in Canadian Men With Metastatic Hormone Sensitive Prostate Cancer in Routine Medical Care

An observational study in Metastatic Hormone-sensitive Prostate Cancer, sponsored by Bayer. Completed at 1 site in Canada. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Bayer · Observational

How we know

Updated Oct 6, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
477
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in Prostatic Neoplasms by Bayer — 11 open to participants now, 16 under way, 1 of them phase 3. Prostatic Neoplasms · Bayer.

Enrollment
25th of 40
477 · median 700
Started
2025
with 2 others
Observational
40 of 75
8 open now
Registered
67th of 75
by date

Among the 75 studies in Prostatic Neoplasms by Bayer, this one is the 25th largest by enrollment of the 40 observational ones that give a count, is one of 3 that started in 2025, is one of 40 observational ones, and was the 67th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

11 of the 75 studies in Prostatic Neoplasms by Bayer are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Prostatic Neoplasms by Bayer, or all of them as a file.
02

Study summary

This is an observational study in which only data are collected from adult Canadian men with metastatic hormone sensitive prostate cancer (mHSPC) are studied. Participants will not receive any advice on treatment or any changes to the healthcare.

Metastatic hormone sensitive prostate cancer is a cancer of the prostate gland, a male reproductive gland found below the bladder. Metastatic means that cancer has spread to other parts of the body. Hormone-sensitive means it can be treated with anti-hormonal therapy such as androgen deprivation therapy (ADT).

ADT lowers the level of testosterone and slows down the growth of cancer cells. However, in some cases, ADT alone is not sufficient and doctors recommend combining it with treatments like Androgen Receptor Pathway Inhibitors (ARPi) and/or docetaxel to stop the growth of cancer cells.

ARPi slow down the growth of the cancer cells by blocking a sex hormone called the androgens from attaching to the protein found in the cancer cells. ARPi includes medicines like apalutamide, darolutamide, and enzalutamide.

Docetaxel is a medicine used to treat different types of cancer and works by stopping the growth and spread of cancer cells. ADT, ARPi, and docetaxel are approved treatments for men with mHSPC in Canada.

The participants in this study are already receiving treatment for mHSPC as part of their routine medical care from their doctors.

03

Conditions studied

  • Metastatic Hormone-sensitive Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Sampling method
Non-probability sample

Study population

This study will include patients from 8 community urology clinics across two Canadian provinces. According to the Canadian Urological Association (CUA), community urologists are defined as non-academic institutions with considerably less access to residents, allied professional support, new technology, research funding, and/or continuous peer-review. Their referral base is primarily family physicians, and their teaching responsibilities include primarily family physicians and nurses.

The 8 community urology clinics will be selected purposefully based on the specific data needs to address the study objectives, taking into consideration factors such as clinic size, and where possible, uptake of treatment intensification to increase the generalizability of the findings.

However, it is acknowledged that this is a convenience sample, and may not accurately represent the wider mHSPC Canadian population.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men aged ≥ 18 years diagnosed with mHSPC verified by radiographic evidence of with Conventional Imaging (CI) or Prostate Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET), and confirmed carcinoma
  • At least 6 months follow-up post-diagnosis period, unless the patient died earlier

Exclusion criteria

Exclusion Criteria:

  • ADT use for >6 months or any use of ARPi (ADT use in the or adjuvant setting where the patient has been off treatment for 12 months or more is allowed)
  • This criterion is to ensure that we are capturing mHSPC patients and not Castration-Resistant Prostate Cancer (mCRPC) patients who have progressed from earlier stages
  • Evidence of inclusion in clinical trials during the study period
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
477 participants (actual)
Patient registry
No

Groups and cohorts

  • Cohort A

    No Androgen Deprivation Therapy (ADT) nor Androgen Receptor Pathway Inhibitor (ARPi) treatment

  • Cohort B

    Androgen Deprivation Therapy (ADT) Monotherapy: Patients initiating or continuing ADT alone for up to 180 days after Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) diagnosis

  • Cohort C

    Androgen Deprivation Therapy (ADT)+Docetaxel: Patients initiating docetaxel within 180 days of start of ADT after Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) diagnosis

  • Cohort D

    Androgen Deprivation Therapy (ADT)+Androgen Receptor Pathway Inhibitor (ARPi): Patients initiating ARPi within 180 days of start of ADT after mHSPC diagnosis

  • Cohort E

    Androgen Deprivation Therapy (ADT)+Androgen Receptor Pathway Inhibitor (ARPi)+Docetaxel: Patients initiating ARPi and docetaxel within 180 days start of ADT after Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) diagnosis

06

What researchers measure

Primary outcomes

  1. Treatment intensification in patients with mHSPC

    The primary outcome of interest is utilization of treatment intensification in patients with mHSPC, including: Frequencies and percentages of patients in each treatment cohort

    Time frame: January 2018 until June 2026

Secondary outcomes

  1. Demographics: age in years

    Data utilized consists of secondary-use data: all data used was collected as part of routine clinical practice (patients' medical records) prior to study initiation

    Time frame: January 2018 until June 2026

  2. Clinical characteristics: date of diagnosis of prostate cancer

    Data utilized consists of secondary-use data: all data used was collected as part of routine clinical practice (patients' medical records) prior to study initiation

    Time frame: January 2018 until June 2026

  3. Clinical characteristics: date of mHSPC diagnosis (as confirmed by radiographic evidence of metastasis with CI or PSMA-PET, and histologically confirmed carcinoma)

    Data utilized consists of secondary-use data: all data used was collected as part of routine clinical practice (patients' medical records) prior to study initiation

    Time frame: January 2018 until June 2026

  4. Clinical characteristics: year of mHSPC diagnosis

    Data utilized consists of secondary-use data: all data used was collected as part of routine clinical practice (patients' medical records) prior to study initiation

    Time frame: January 2018 until June 2026

  5. Clinical characteristics: Eastern Cooperative Oncology Group (ECOG) score

    Data utilized consists of secondary-use data: all data used was collected as part of routine clinical practice (patients' medical records) prior to study initiation

    Time frame: January 2018 until June 2026

  6. Clinical characteristics: Gleason score

    Data utilized consists of secondary-use data: all data used was collected as part of routine clinical practice (patients' medical records) prior to study initiation

    Time frame: January 2018 until June 2026

  7. Clinical characteristics: comorbidities (Charlson Comorbidity Index)

    Data utilized consists of secondary-use data: all data used was collected as part of routine clinical practice (patients' medical records) prior to study initiation

    Time frame: January 2018 until June 2026

  8. Clinical characteristics: disease volume/risk at baseline

    Data utilized consists of secondary-use data: all data used was collected as part of routine clinical practice (patients' medical records) prior to study initiation

    Time frame: January 2018 until June 2026

  9. Clinical characteristics: radiological evidence of metastases (number and site) at time of initial mHSPC diagnosis

    Data utilized consists of secondary-use data: all data used was collected as part of routine clinical practice (patients' medical records) prior to study initiation

    Time frame: January 2018 until June 2026

  10. Physician characteristics: practice size

    Physician characteristics that are related to treatment intensification. Data was extracted from the EHR where available, and via communication with the clinicians.

    Time frame: January 2018 until June 2026

  11. Physician characteristics: years in practice

    Physician characteristics that are related to treatment intensification. Data was extracted from the EHR where available, and via communication with the clinicians

    Time frame: January 2018 until June 2026

  12. Physician characteristics: number of patients seen annually with prostate cancer

    Physician characteristics that are related to treatment intensification. Data was extracted from the EHR where available, and via communication with the clinicians

    Time frame: January 2018 until June 2026

  13. Physician characteristics: treatment areas of expertise

    Physician characteristics that are related to treatment intensification. Data was extracted from the EHR where available, and via communication with the clinicians.

    Time frame: January 2018 until June 2026

  14. Reasons for treatment discontinuation and/or changing treatment by treatment cohort

    Reasons for treatment discontinuation and/or changing treatment by treatment cohort, including: * Frequency and percentages of patients discontinuing/changing treatment due to AEs (and treatment-relatedness, if possible) * Frequency and percentages of patients discontinuing/changing treatment due to progression to mCRPC * Frequency and percentages of patients discontinuing treatment due to death * Frequency and percentages of patients discontinuing/changing treatment due to any other reason

    Time frame: January 2018 until June 2026

  15. Time to treatment discontinuation (TTD)

    TTD will be measured from start of study treatment (index date 2) until discontinuation of ADT in monotherapy regimens or discontinuation of ARPi in doublet or triplet regimens or discontinuation of docetaxel within \< 6 cycles in the docetaxel regimens. Treatment discontinuation will be defined as the last date treatment is given

    Time frame: January 2018 until June 2026

  16. mCRPC real-world progression free survival (rwPFS)

    rwPFS will be measured from mHSPC diagnosis (index date 1) until date of progression as documented in physician notes or rising PSA levels (using PCW3 definition) despite castrate testosterone levels, where available, or date of death

    Time frame: January 2018 until June 2026

  17. Referral patterns for intensification among patients with mHSPC

    Determine if the study can identify a pattern in which mHSPC patients can be candidates for intensification therapy, based on the patient data.

    Time frame: January 2018 until June 2026

  18. Docetaxel dosage adjustments

    Time frame: January 2018 until June 2026

07

Study locations

1 site
  • Pentavere
    Toronto, Ontario M6G 1A1, Canada
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2025 to primary completion in Jun 2026, 16 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Dec 2026 → Jun 2026 and completion Dec 2026 → Jun 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2025
First posted
Mar 13, 2025
StartActual
Feb 28, 2025
Primary completionActual
Jun 30, 2026was Dec 2026
CompletionActual
Jun 30, 2026was Dec 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 6, 2026
Primary completion
Dec 31, 2026→Jun 30, 2026 (actual)
Oct 6, 2026
Study completion
Dec 31, 2026→Jun 30, 2026 (actual)
Oct 6, 2026
Enrollment
700 (estimated)→477 (actual)
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Active, not recruiting→Completed
    Primary completion Dec 31, 2026→Jun 30, 2026 (now actual)
    Study completion Dec 31, 2026→Jun 30, 2026 (now actual)
    Enrollment 700 (estimated)→477 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06874114
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Mar 13, 2025
Start date
Feb 28, 2025
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026
Last update
Oct 6, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion